Abstract
Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. A high variability of the immunoreactive values was observed by analysing different preparations of radiolabelled MOv18 (from 12 to 21% on OvCa432 and from 22 to 56% on IGROV1) and by using the same radiolabelled preparation (12% on OvCa432 and 51% on IGROV1). Since the variability could be due to the target cells, we set up an alternative binding assay using the anti-idiotypic MAb anti-Id18.1 directed against a private idiotype closely associated with the MOv18 paratope. Three different experiments carried out with the anti-idiotypic MAb gave reproducible results with an immunoreactive range from 71 to 83%. A direct comparison between the reactivity of the same 125I-MOv18 preparation on anti-Id18.1 and on IGROV1 confirmed the higher value of the immunoreactive fraction estimated on the more homogeneous anti-idiotypic reagent (71%), rather than on the tumour cells (56%). These data suggest that anti-idiotypic MAbs could represent suitable reagents for the evaluation of the immunoreactivity of an antibody preparation after radiolabelling and before in vivo administration.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Colnaghi M. I., Buraggi G. L., Canevari S., Di Re F., Leoni F., Mangioni C., Ménard S., Orlandi R. Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches. Int J Rad Appl Instrum B. 1989;16(6):633–636. doi: 10.1016/0883-2897(89)90087-1. [DOI] [PubMed] [Google Scholar]
- Colnaghi M. I., Canevari S., Ménard S. Monoclonal antibodies in immunodiagnosis and immunotherapy of human cancer. Eur J Surg Oncol. 1988 Feb;14(1):1–7. [PubMed] [Google Scholar]
- Herrmann J. E. Quantitation of antibodies immobilized on plastics. Methods Enzymol. 1981;73(Pt B):239–244. doi: 10.1016/0076-6879(81)73068-4. [DOI] [PubMed] [Google Scholar]
- Larson S. M. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med. 1985 May;26(5):538–545. [PubMed] [Google Scholar]
- Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P. A., Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 3;72(1):77–89. doi: 10.1016/0022-1759(84)90435-6. [DOI] [PubMed] [Google Scholar]
- Matzku S., Kirchgessner H., Dippold W. G., Brüggen J. Immunoreactivity of monoclonal anti-melanoma antibodies in relation to the amount of radioactive iodine substituted to the antibody molecule. Eur J Nucl Med. 1985;11(6-7):260–264. doi: 10.1007/BF00279081. [DOI] [PubMed] [Google Scholar]
- Miotti S., Canevari S., Ménard S., Mezzanzanica D., Porro G., Pupa S. M., Regazzoni M., Tagliabue E., Colnaghi M. I. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987 Mar 15;39(3):297–303. doi: 10.1002/ijc.2910390306. [DOI] [PubMed] [Google Scholar]